PTC Therapeutics PIVOT-HD study endorsed* by EHDN

Study aims and goal: The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 and placebo in participants with HD.
No. of study participants and sites: This phase IIa study aims to recruit participants from sites in Australia, France, Germany, Netherlands, the UK and the US.
For further information see the clinical trial registration.